RxDoctor Payments Data

Hilario Yankey, MD

Radiation Oncology · Philadelphia, PANPI 1407416795

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 8 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 7 manufacturers reported payments, led by Reflexion Medical, Inc. at 41.5% of the total. Reporting peaked in 2022 at $166 and has fallen 58.5% since, to $69 in 2025. That places this record below the midpoint for radiation oncology clinicians in PA, where the typical reported total is $405.

$401in general payments, 2019–2025

Across 8 payments — averaging $50.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Reflexion Medical, Inc.$166
  • Boston Scientific$82
  • Johnson & Johnson$45
  • Blue Earth Diagnostics$37
  • Daiichi Sankyo Inc.$27
  • Tersera Therapeutics LLC$24
  • plus $20 from 1 others

What the payments were for

  • Food & beverage$401100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$401 in reported general payments places this provider in the 45th percentile of 339 radiation oncology providers in Pennsylvania.

See all radiation oncology providers in Pennsylvania →

Medicare billing

Part B allowed, 2024
$74,309
Medicare patients
114
Services billed
781

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Lidocaine Hcl ViscousLidocaine Hcl17$442
Tamsulosin Hcl15$296
Gabapentin17$220

Paid to pharmacies, not to this prescriber.

Other radiation oncology in Philadelphia

See the full list for Pennsylvania →

Where these figures come from

Is this you, or does something look wrong? →